Pages that link to "Q44718397"

The following pages link to A phase 1a clinical trial of LYM-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies (Q44718397):

Displaying 25 items.

• The emerging role of radioimmunotherapy in haematological malignancies (Q33904384) (← links)
• Novel therapies for chronic lymphocytic leukemia (Q34304235) (← links)
• Choosing an optimal radioimmunotherapy dose for clinical response (Q34551589) (← links)
• HLA class II antibodies in the treatment of hematologic malignancies (Q35206356) (← links)
• Targeted therapy for hematologic malignancies (Q36108610) (← links)
• Novel antibodies against follicular non-Hodgkin’s lymphoma (Q37887147) (← links)
• Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines (Q40135352) (← links)
• Fully human antibody exhibits pan-human leukocyte antigen-DR recognition and high in vitro/vivo efficacy against human leukocyte antigen-DR-positive lymphomas (Q40146896) (← links)
• HLA Class II Antibodies Recruit G-CSF Activated Neutrophils for Treatment of B Cell Malignancies (Q40887973) (← links)
• The potential for immunoconjugates in lymphoma therapy. (Q41615778) (← links)
• Critical Lym-1 binding residues on polymorphic HLA-DR molecules (Q41706748) (← links)
• Chimaeric Lym-1 monoclonal antibody-mediated cytolysis by neutrophils from G-CSF-treated patients: stimulation by GM-CSF and role of Fc gamma -receptors. (Q42026336) (← links)
• FMLP- and TNF-stimulated monoclonal Lym-1 antibody-dependent lysis of B lymphoblastoid tumour targets by neutrophils. (Q42033770) (← links)
• Antigenicity of mouse monoclonal antibodies. A study on the variable region of the heavy chain (Q42800176) (← links)
• Monoclonal LYM-1 antibody-dependent cytolysis by human neutrophils exposed to GM-CSF: auto-regulation of target cell attack by cathepsin G. (Q44606565) (← links)
• Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study (Q44797709) (← links)
• A selective high affinity ligand (SHAL) designed to bind to an over-expressed human antigen on non-Hodgkin's lymphoma also binds to canine B-cell lymphomas (Q46263520) (← links)
• Lym-1 Chimeric Antigen Receptor T Cells Exhibit Potent Anti-Tumor Effects against B-Cell Lymphoma. (Q47271647) (← links)
• Humanization and characterization of the anti-HLA-DR antibody 1D10. (Q48350859) (← links)
• Kinetics of W3/25 anti-rat CD4 monoclonal antibody (Q61472039) (← links)
• Radionuclide Therapy of Leukemias and Multiple Myeloma (Q61755948) (← links)
• Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19 (Q71669579) (← links)
• Non-Hodgkin's lymphoma (Q71779941) (← links)
• Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma (Q77565327) (← links)
• Development of novel monoclonal antibodies to dog leukocyte antigen DR displaying direct and immune-mediated cytotoxicity toward canine lymphoma cell lines (Q88156125) (← links)